AstraZeneca’s NSCLC combination misses primary endpoint in Phase III LATIFY trial

AstraZeneca has announced that its combination therapy of ceralasertib and Imfinzi (durvalumab) for locally advanced or metastatic non-small cell lung cancer (NSCLC) did not meet the primary endpoint in the Phase III LATIFY trial (NCT05450692). The study assessed patients without actionable genomic alterations whose disease progressed following prior immunotherapy and platinum-based chemotherapy.

Participants received ceralasertib 240 mg twice daily for seven days plus 1,500 mg Imfinzi every four weeks, or standard-of-care docetaxel every three weeks. The combination did not improve overall survival compared with docetaxel.

The regimen was generally well tolerated, with a safety profile consistent with each drug and no new safety concerns. AstraZeneca plans to present detailed LATIFY trial data at an upcoming medical meeting.

29-01-2026